Trifluoroacetic acid → HCID 53794364、化合物
反応式
Cl.Cl.[NH2:3][C:4]1[C:13]2[C:8](=[CH:9][C:10]([CH2:14][N:15]3[CH2:20][CH2:19][NH:18][CH2:17][C:16]3=[O:21])=[CH:11][CH:12]=2)[N:7]=[CH:6][N:5]=1.Br[CH2:23][C:24]1[S:28][C:27]2[CH:29]=[C:30]([Cl:33])[CH:31]=[CH:32][C:26]=2[CH:25]=1.C([O-])([O-])=O.[K+].[K+].FC(F)(F)C(O)=O>CN(C=O)C.O>[NH2:3][C:4]1[C:13]2[C:8](=[CH:9][C:10]([CH2:14][N:15]3[CH2:20][CH2:19][N:18]([CH2:23][C:24]4[S:28][C:27]5[CH:29]=[C:30]([Cl:33])[CH:31]=[CH:32][C:26]=5[CH:25]=4)[CH2:17][C:16]3=[O:21])=[CH:11][CH:12]=2)[N:7]=[CH:6][N:5]=1参加物
実験手順
To a solution of 1-(4-aminoquinazoline-7-ylmethyl)piperazine-2-one bishydrochloride (1.84 g, 5.73 mmol), EXAMPLE 72, in DMF (20 mL) is added 2-bromomethyl-6-chloro-benzo[b]thiophene, EXAMPLE 5, (1.5 g, 5.73 mmol) and K2CO3 (4.0 g, 28.7 mmol). The solution is stirred for 16 hours. After this time, the solution is diluted with water. The solution is acidified with trifluoroacetic acid. The product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0.1% TFA) to 50% CH3CN/H2O (0.1% TFA). The appropriate collected fractions are lyopholized to afford the title compound as a white solid. 1H NMR (d6-DMSO, 300 MHz) δ9.78 (bs, 3H), 8.82 (s, 1H), 8.34 (d, 1H), 8.07 (s, 1H), 7.81 (d, 1H), 7.63 (d, 1H), 7.51 (s, 1H), 7.32 (m, 2H), 4.71 (s, 2H), 3.95 (s, 2H), 3.28 (m, 4H), 2.80 (m, 2H).
後処理
- customThe product is purified by RP-HPLC
- washeluting in a gradient of 10% CH3CN/H2O (0.1% TFA) to 50% CH3CN/H2O (0.1% TFA)
- customThe appropriate collected fractions
出典と根拠
- ORDレコード
- ord-d1f7f230aedc41d0bb697d74b7e3ffc2
- 出典データセット
- uspto-grants-2009_11
- 特許番号
- US07612075B2
反応ノート
読み込み中…